MeiraGTx : Results of a Phase 1, Open-label, Dose-escalation

Results of a Phase 1, Open-label,Dose-escalation Study of Gene Therapy with AAV2-hAQP1 as Treatment for Grade 2 and 3 Radiation-induced Late Xerostomia and Parotid Gland Hypofunction -...

Related Keywords

United States , American , Michaelt Brennan , , Dose Escalation Study , Gene Therapy , Late Xerostomia , Parotid Gland Hypofunction , Induced Xerostomia , Unmet Medical Need , Study Design , Symptom Inventory , Change Questionnaire , Baseline Characteristics , Total Xerostomia Questionnaire , Dry Mouth , Relatedtreatment Emergent Adverse Events , Xerostomia Questionnaire , Total Score , Case Control Study , Head And Neck Cancer , Markets ,